{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:08:25Z","timestamp":1758280105348},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00059-022-05129-3","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T15:02:58Z","timestamp":1658415778000},"page":"426-433","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Herz und Diabetes"],"prefix":"10.1007","volume":"47","author":[{"given":"Martin","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance C. F. M. J.","family":"Baaten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Noels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Sch\u00fctt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"5129_CR1","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1681\/ASN.2014070714","volume":"26","author":"S Thompson","year":"2015","unstructured":"Thompson\u00a0S, James\u00a0M, Wiebe\u00a0N et\u00a0al (2015) Cause of death in patients with reduced kidney function. J\u00a0Am Soc Nephrol 26:2504\u20132511. https:\/\/doi.org\/10.1681\/ASN.2014070714","journal-title":"J Am Soc Nephrol"},{"key":"5129_CR2","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go\u00a0AS, Chertow\u00a0GM, Fan\u00a0D et\u00a0al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N\u00a0Engl J Med 351:1296\u20131305. https:\/\/doi.org\/10.1056\/NEJMoa041031","journal-title":"N Engl J Med"},{"key":"5129_CR3","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1056\/NEJMra2201153","volume":"386","author":"AS Levey","year":"2022","unstructured":"Levey\u00a0AS, Grams\u00a0ME, Inker\u00a0LA (2022) Uses of GFR and albuminuria level in acute and chronic kidney disease. N\u00a0Engl J Med 386:2120\u20132128. https:\/\/doi.org\/10.1056\/NEJMra2201153","journal-title":"N Engl J Med"},{"key":"5129_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.7326\/0003-4819-137-7-200210010-00006","volume":"137","author":"MG Shlipak","year":"2002","unstructured":"Shlipak\u00a0MG, Heidenreich\u00a0PA, Noguchi\u00a0H et\u00a0al (2002) Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137:555\u2013562. https:\/\/doi.org\/10.7326\/0003-4819-137-7-200210010-00006","journal-title":"Ann Intern Med"},{"key":"5129_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"CS Fox","year":"2010","unstructured":"Fox\u00a0CS, Muntner\u00a0P, Chen\u00a0AY et al (2010) Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a\u00a0report from the national cardiovascular data acute coronary treatment and intervention outcomes network registry. Circulation 121:357\u2013365. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.865352","journal-title":"Circulation"},{"key":"5129_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40697-014-0021-x","volume":"1","author":"MM Sood","year":"2014","unstructured":"Sood\u00a0MM, Bota\u00a0SE, McArthur\u00a0E et al (2014) The three-year incidence of major hemorrhage among older adults initiating chronic dialysis. Can J Kidney Health Dis 1:21. https:\/\/doi.org\/10.1186\/s40697-014-0021-x","journal-title":"Can J Kidney Health Dis"},{"key":"5129_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin\u00a0L, Becker\u00a0RC, Budaj\u00a0A et\u00a0al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N\u00a0Engl J Med 361:1045\u20131057. https:\/\/doi.org\/10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"key":"5129_CR8","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott\u00a0SD, Braunwald\u00a0E, McCabe\u00a0CH et\u00a0al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N\u00a0Engl J Med 357:2001\u20132015. https:\/\/doi.org\/10.1056\/NEJMoa0706482","journal-title":"N Engl J Med"},{"key":"5129_CR9","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","volume":"367","author":"MT Roe","year":"2012","unstructured":"Roe\u00a0MT, Armstrong\u00a0PW, Fox\u00a0KA et\u00a0al (2012) Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N\u00a0Engl J Med 367:1297\u20131309. https:\/\/doi.org\/10.1056\/NEJMoa1205512","journal-title":"N Engl J Med"},{"key":"5129_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1055\/s-2004-835678","volume":"30","author":"P Boccardo","year":"2004","unstructured":"Boccardo\u00a0P, Remuzzi\u00a0G, Galbusera\u00a0M (2004) Platelet dysfunction in renal failure. Semin Thromb Hemost 30:579\u2013589. https:\/\/doi.org\/10.1055\/s-2004-835678","journal-title":"Semin Thromb Hemost"},{"key":"5129_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jth.13904","volume":"16","author":"G Ocak","year":"2018","unstructured":"Ocak\u00a0G, Rookmaaker\u00a0MB, Algra\u00a0A et\u00a0al (2018) Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a\u00a0cohort study. J\u00a0Thromb Haemost 16:65\u201373. https:\/\/doi.org\/10.1111\/jth.13904","journal-title":"J Thromb Haemost"},{"key":"5129_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/ki.2015.117","volume":"88","author":"KU Eckardt","year":"2015","unstructured":"Eckardt\u00a0KU, Gillespie\u00a0IA, Kronenberg\u00a0F et\u00a0al (2015) High cardiovascular event rates occur within the first weeks of starting hemodialysis. Kidney Int 88:1117\u20131125. https:\/\/doi.org\/10.1038\/ki.2015.117","journal-title":"Kidney Int"},{"key":"5129_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2215\/CJN.04100321","volume":"17","author":"C Baaten","year":"2022","unstructured":"Baaten\u00a0C, Schroer\u00a0JR, Floege\u00a0J et\u00a0al (2022) Platelet abnormalities in CKD and their implications for antiplatelet therapy. Clin J Am Soc Nephrol 17:155\u2013170. https:\/\/doi.org\/10.2215\/CJN.04100321","journal-title":"Clin J Am Soc Nephrol"},{"key":"5129_CR14","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1681\/ASN.2016030336","volume":"28","author":"K Schuett","year":"2017","unstructured":"Schuett\u00a0K, Savvaidis\u00a0A, Maxeiner\u00a0S et\u00a0al (2017) Clot structure: a potent mortality risk factor in patients on hemodialysis. J\u00a0Am Soc Nephrol 28:1622\u20131630. https:\/\/doi.org\/10.1681\/ASN.2016030336","journal-title":"J Am Soc Nephrol"},{"key":"5129_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1159\/000169033","volume":"16","author":"A Vecino","year":"1996","unstructured":"Vecino\u00a0A, Teruel\u00a0JL, Navarro\u00a0JL, Cesar\u00a0JM (1996) Plasma phospholipids and platelet function in uremic patients. Am J Nephrol 16:409\u2013411. https:\/\/doi.org\/10.1159\/000169033","journal-title":"Am J Nephrol"},{"key":"5129_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/archinte.1970.00310110093013","volume":"126","author":"HI Horowitz","year":"1970","unstructured":"Horowitz\u00a0HI (1970) Uremic toxins and platelet function. Arch Intern Med 126:823\u2013826","journal-title":"Arch Intern Med"},{"key":"5129_CR17","doi-asserted-by":"publisher","first-page":"e0212237","DOI":"10.1371\/journal.pone.0212237","volume":"14","author":"A Gackler","year":"2019","unstructured":"Gackler\u00a0A, Rohn\u00a0H, Lisman\u00a0T et al (2019) Evaluation of hemostasis in patients with end-stage renal disease. PLoS ONE 14:e212237. https:\/\/doi.org\/10.1371\/journal.pone.0212237","journal-title":"PLoS ONE"},{"key":"5129_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0049-3848(83)90080-4","volume":"30","author":"M Winter","year":"1983","unstructured":"Winter\u00a0M, Frampton\u00a0G, Bennett\u00a0A et\u00a0al (1983) Synthesis of thromboxane B2 in uraemia and the effects of dialysis. Thromb Res 30:265\u2013272. https:\/\/doi.org\/10.1016\/0049-3848(83)90080-4","journal-title":"Thromb Res"},{"key":"5129_CR19","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1055\/s-0040-1705138","volume":"4","author":"C Makhloufi","year":"2020","unstructured":"Makhloufi\u00a0C, Crescence\u00a0L, Darbousset\u00a0R et al (2020) Assessment of thrombotic and bleeding tendency in two mouse models of chronic kidney disease: adenine-diet and 5\/6th nephrectomy. TH Open 4:e66\u2013e76. https:\/\/doi.org\/10.1055\/s-0040-1705138","journal-title":"TH Open"},{"key":"5129_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-0038-1647640","volume":"60","author":"MP Gordge","year":"1988","unstructured":"Gordge\u00a0MP, Faint\u00a0RW, Rylance\u00a0PB, Neild\u00a0GH (1988) Platelet function and the bleeding time in progressive renal failure. Thromb Haemost 60:83\u201387","journal-title":"Thromb Haemost"},{"key":"5129_CR21","first-page":"16704","volume":"8","author":"GY Lu","year":"2015","unstructured":"Lu\u00a0GY, Xu\u00a0RJ, Zhang\u00a0SH et\u00a0al (2015) Alteration of circulatory platelet microparticles and endothelial microparticles in patients with chronic kidney disease. Int J Clin Exp Med 8:16704\u201316708","journal-title":"Int J Clin Exp Med"},{"key":"5129_CR22","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1681\/ASN.2011121175","volume":"23","author":"F Duranton","year":"2012","unstructured":"Duranton\u00a0F, Cohen\u00a0G, De Smet\u00a0R et\u00a0al (2012) Normal and pathologic concentrations of uremic toxins. J\u00a0Am Soc Nephrol 23:1258\u20131270. https:\/\/doi.org\/10.1681\/ASN.2011121175","journal-title":"J Am Soc Nephrol"},{"key":"5129_CR23","first-page":"349","volume":"2","author":"No authors listed","year":"1988","unstructured":"No authors listed (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS\u20112. ISIS\u20112 (second international study of infarct survival) collaborative group. Lancet 2:349\u2013360","journal-title":"Lancet"},{"key":"5129_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti\u00a0J, Wijns\u00a0W, Saraste\u00a0A et\u00a0al (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart\u00a0J 41:407\u2013477. https:\/\/doi.org\/10.1093\/eurheartj\/ehz425","journal-title":"Eur Heart J"},{"key":"5129_CR25","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"ASC Group","year":"2018","unstructured":"Group\u00a0ASC, Bowman\u00a0L, Mafham\u00a0M et\u00a0al (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N\u00a0Engl J Med 379:1529\u20131539. https:\/\/doi.org\/10.1056\/NEJMoa1804988","journal-title":"N Engl J Med"},{"key":"5129_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/jth.13211","volume":"14","author":"A Plzin","year":"2016","unstructured":"Plzin\u00a0A, Dannenberg\u00a0L, Sansone\u00a0R et\u00a0al (2016) Antiplatelet effects of aspirin in chronic kidney disease patients. J\u00a0Thromb Haemost 14:375\u2013380. https:\/\/doi.org\/10.1111\/jth.13211","journal-title":"J Thromb Haemost"},{"key":"5129_CR27","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/eurjpc\/zwab132","volume":"28","author":"S Pallikadavath","year":"2022","unstructured":"Pallikadavath\u00a0S, Ashton\u00a0L, Brunskill\u00a0NJ et al (2022) Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a\u00a0systematic review and meta-analysis. Eur J Prev Cardiol 28:1953\u20131960. https:\/\/doi.org\/10.1093\/eurjpc\/zwab132","journal-title":"Eur J Prev Cardiol"},{"key":"5129_CR28","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1161\/CIRCULATIONAHA.118.032078","volume":"138","author":"L Bonello","year":"2018","unstructured":"Bonello\u00a0L, Angiolillo\u00a0DJ, Aradi\u00a0D, Sibbing\u00a0D (2018) P2Y12-ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes. Circulation 138:1582\u20131596. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.032078","journal-title":"Circulation"},{"key":"5129_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","volume":"53","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli\u00a0M, Bueno\u00a0H, Byrne\u00a0RA et\u00a0al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 53:34\u201378. https:\/\/doi.org\/10.1093\/ejcts\/ezx334","journal-title":"Eur J Cardiothorac Surg"},{"key":"5129_CR30","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine\u00a0GN, Bates\u00a0ER, Bittl\u00a0JA et al (2016) 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 134:e123\u2013155. https:\/\/doi.org\/10.1161\/CIR.0000000000000404","journal-title":"Circulation"},{"key":"5129_CR31","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.amjcard.2009.06.049","volume":"104","author":"SH Park","year":"2009","unstructured":"Park\u00a0SH, Kim\u00a0W, Park\u00a0CS et\u00a0al (2009) A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 104:1292\u20131295. https:\/\/doi.org\/10.1016\/j.amjcard.2009.06.049","journal-title":"Am J Cardiol"},{"key":"5129_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.amjcard.2013.12.018","volume":"113","author":"F Mangiacapra","year":"2014","unstructured":"Mangiacapra\u00a0F, Cavallari\u00a0I, Barbato\u00a0E et\u00a0al (2014) Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. Am J Cardiol 113:1124\u20131129. https:\/\/doi.org\/10.1016\/j.amjcard.2013.12.018","journal-title":"Am J Cardiol"},{"key":"5129_CR33","doi-asserted-by":"publisher","first-page":"e001683","DOI":"10.1161\/CIRCINTERVENTIONS.115.001683","volume":"8","author":"U Baber","year":"2015","unstructured":"Baber\u00a0U, Mehran\u00a0R, Kirtane\u00a0AJ et al (2015) Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the assessment of dual antiplatelet therapy with drug-eluting stents registry. Circ Cardiovasc Interv 8:e1683. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.115.001683","journal-title":"Circ Cardiovasc Interv"},{"key":"5129_CR34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","volume":"155","author":"PJ Best","year":"2008","unstructured":"Best\u00a0PJ, Steinhubl\u00a0SR, Berger\u00a0PB et al (2008) The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the clopidogrel for the reduction of events during observation (CREDO) trial. Am Heart\u00a0J 155:687\u2013693. https:\/\/doi.org\/10.1016\/j.ahj.2007.10.046","journal-title":"Am Heart J"},{"key":"5129_CR35","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.amjcard.2009.01.342","volume":"103","author":"A Dasgupta","year":"2009","unstructured":"Dasgupta\u00a0A, Steinhubl\u00a0SR, Bhatt\u00a0DL et\u00a0al (2009) Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 103:1359\u20131363. https:\/\/doi.org\/10.1016\/j.amjcard.2009.01.342","journal-title":"Am J Cardiol"},{"key":"5129_CR36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.rec.2021.05.002","volume":"74","author":"JP Collet","year":"2021","unstructured":"Collet\u00a0JP, Thiele\u00a0H, Barbato\u00a0E et al (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Rev Esp Cardiol (Engl Ed) 74:544. https:\/\/doi.org\/10.1016\/j.rec.2021.05.002","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"5129_CR37","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.rec.2017.11.010","volume":"70","author":"B Ibanez","year":"2017","unstructured":"Ibanez\u00a0B, James\u00a0S, Agewall\u00a0S et al (2017) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed) 70:1082. https:\/\/doi.org\/10.1016\/j.rec.2017.11.010","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"5129_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bcp.13436","volume":"84","author":"H Wang","year":"2018","unstructured":"Wang\u00a0H, Qi\u00a0J, Li\u00a0Y et\u00a0al (2018) Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. Br J Clin Pharmacol 84:88\u201396. https:\/\/doi.org\/10.1111\/bcp.13436","journal-title":"Br J Clin Pharmacol"},{"key":"5129_CR39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ijcard.2015.02.077","volume":"184","author":"P Deharo","year":"2015","unstructured":"Deharo\u00a0P, Pankert\u00a0M, Quilici\u00a0J et\u00a0al (2015) Chronic kidney disease has a\u00a0significant impact on platelet inhibition of new P2Y12 inhibitors. Int J Cardiol 184:428\u2013430. https:\/\/doi.org\/10.1016\/j.ijcard.2015.02.077","journal-title":"Int J Cardiol"},{"key":"5129_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.ajkd.2012.05.001","volume":"60","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos\u00a0D, Xanthopoulou\u00a0I, Plakomyti\u00a0TE et al (2012) Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis 60:332\u2013333. https:\/\/doi.org\/10.1053\/j.ajkd.2012.05.001","journal-title":"Am J Kidney Dis"},{"key":"5129_CR41","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1111\/j.1538-7836.2011.04531.x","volume":"9","author":"D Alexopoulos","year":"2011","unstructured":"Alexopoulos\u00a0D, Panagiotou\u00a0A, Xanthopoulou\u00a0I et al (2011) Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J\u00a0Thromb Haemost 9:2379\u20132385. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04531.x","journal-title":"J Thromb Haemost"},{"key":"5129_CR42","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.jcin.2017.02.047","volume":"10","author":"U Baber","year":"2017","unstructured":"Baber\u00a0U, Chandrasekhar\u00a0J, Sartori\u00a0S et\u00a0al (2017) Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the PROMETHEUS study. JACC Cardiovasc Interv 10:2017\u20132025. https:\/\/doi.org\/10.1016\/j.jcin.2017.02.047","journal-title":"JACC Cardiovasc Interv"},{"key":"5129_CR43","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/heartjnl-2017-312436","volume":"104","author":"R Edfors","year":"2018","unstructured":"Edfors\u00a0R, Sahlen\u00a0A, Szummer\u00a0K et\u00a0al (2018) Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function. Heart 104:1575\u20131582. https:\/\/doi.org\/10.1136\/heartjnl-2017-312436","journal-title":"Heart"},{"key":"5129_CR44","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jcin.2020.07.032","volume":"13","author":"G Ndrepepa","year":"2020","unstructured":"Ndrepepa\u00a0G, Kastrati\u00a0A, Menichelli\u00a0M et\u00a0al (2020) Ticagrelor or prasugrel in patients with acute coronary syndromes and diabetes mellitus. JACC Cardiovasc Interv 13:2238\u20132247. https:\/\/doi.org\/10.1016\/j.jcin.2020.07.032","journal-title":"JACC Cardiovasc Interv"},{"key":"5129_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2215\/CJN.12120720","volume":"16","author":"TA Mavrakanas","year":"2021","unstructured":"Mavrakanas\u00a0TA, Kamal\u00a0O, Charytan\u00a0DM (2021) Prasugrel and ticagrelor in patients with drug-eluting stents and kidney failure. Clin J Am Soc Nephrol 16:757\u2013764. https:\/\/doi.org\/10.2215\/CJN.12120720","journal-title":"Clin J Am Soc Nephrol"},{"key":"5129_CR46","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing\u00a0D, Aradi\u00a0D, Jacobshagen\u00a0C et al (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a\u00a0randomised, open-label, multicentre trial. Lancet 390:1747\u20131757. https:\/\/doi.org\/10.1016\/S0140-6736(17)32155-4","journal-title":"Lancet"},{"key":"5129_CR47","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","volume":"381","author":"DMF Claassens","year":"2019","unstructured":"Claassens\u00a0DMF, Vos\u00a0GJA, Bergmeijer\u00a0TO et al (2019) A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N\u00a0Engl J Med 381:1621\u20131631. https:\/\/doi.org\/10.1056\/NEJMoa1907096","journal-title":"N Engl J Med"},{"key":"5129_CR48","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/ckj\/sfaa037","volume":"13","author":"S Park","year":"2020","unstructured":"Park\u00a0S, Kim\u00a0Y, Jo\u00a0HA et al (2020) Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients. Clin Kidney\u00a0J 13:803\u2013812. https:\/\/doi.org\/10.1093\/ckj\/sfaa037","journal-title":"Clin Kidney J"},{"key":"5129_CR49","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12916-018-1145-0","volume":"16","author":"A Covic","year":"2018","unstructured":"Covic\u00a0A, Genovesi\u00a0S, Rossignol\u00a0P et\u00a0al (2018) Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Med 16:158. https:\/\/doi.org\/10.1186\/s12916-018-1145-0","journal-title":"BMC Med"},{"key":"5129_CR50","doi-asserted-by":"publisher","first-page":"e009995","DOI":"10.1161\/JAHA.118.009995","volume":"7","author":"SN de Chickera","year":"2018","unstructured":"de Chickera\u00a0SN, Bota\u00a0SE, Kuwornu\u00a0JP et al (2018) Albuminuria, reduced kidney function, and the risk of ST- and non-ST-segment-elevation myocardial infarction. J\u00a0Am Heart Assoc 7:e9995. https:\/\/doi.org\/10.1161\/JAHA.118.009995","journal-title":"J Am Heart Assoc"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05129-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-022-05129-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05129-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T14:17:56Z","timestamp":1664547476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-022-05129-3"}},"subtitle":["Thrombozytenfunktion und antithrombozyt\u00e4re Therapie bei chronischer Nierenerkrankung"],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["5129"],"URL":"https:\/\/doi.org\/10.1007\/s00059-022-05129-3","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"28 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Berger, C.C.F.M.J.\u00a0Baaten, H.\u00a0Noels, N.\u00a0Marx und K.\u00a0Sch\u00fctt geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}